Comparative Pharmacology
Head-to-head clinical analysis: ABACAVIR SULFATE LAMIVUDINE versus EMTRICITABINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ABACAVIR SULFATE LAMIVUDINE versus EMTRICITABINE.
ABACAVIR SULFATE; LAMIVUDINE vs EMTRICITABINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Abacavir is a nucleoside reverse transcriptase inhibitor (NRTI) that, after intracellular phosphorylation to carbovir triphosphate, competes with natural deoxyguanosine triphosphate for incorporation into viral DNA, causing chain termination. Lamivudine is an NRTI that, after phosphorylation to lamivudine triphosphate, inhibits HIV-1 reverse transcriptase via incorporation into viral DNA, resulting in chain termination.
Nucleoside reverse transcriptase inhibitor; phosphorylated to emtricitabine triphosphate which competes with endogenous deoxycytidine triphosphate and incorporates into viral DNA causing chain termination.
One tablet (abacavir 600 mg/lamivudine 300 mg) once daily, in combination with other antiretrovirals.
200 mg orally once daily, typically in combination with other antiretroviral agents.
None Documented
None Documented
Clinical Note
moderateEmtricitabine + Ribavirin
"Emtricitabine may increase the hepatotoxic activities of Ribavirin."
Clinical Note
moderateLamivudine + Emtricitabine
"The risk or severity of adverse effects can be increased when Lamivudine is combined with Emtricitabine."
Clinical Note
moderateGanciclovir + Emtricitabine
"The risk or severity of adverse effects can be increased when Ganciclovir is combined with Emtricitabine."
Clinical Note
moderateValganciclovir + Emtricitabine
Abacavir: 1.5 h; Lamivudine: 5-7 h (intracellular 10-15 h). Clinical context: Both support twice-daily dosing; lamivudine's longer intracellular half-life allows once-daily dosing.
Terminal elimination half-life is approximately 10 hours (range 8–12 hours) in adults with normal renal function; prolonged to >20 hours in severe renal impairment (CrCl <30 mL/min).
Renal: Abacavir ~83% (metabolites), Lamivudine ~70% (unchanged). Fecal: Abacavir ~16%, Lamivudine minimal. Biliary: negligible.
Renal: approximately 86% of the dose is excreted unchanged in urine via glomerular filtration and active tubular secretion. Biliary/fecal: minimal (<14% as unchanged drug and metabolites in feces).
Category A/B
Category C
NRTI
Antiretroviral, NRTI
"The risk or severity of adverse effects can be increased when Valganciclovir is combined with Emtricitabine."